Leopold L.
- Country
- Germany
- Department
- Gastroenterologische Schwerpunktpraxis Prof. Dr. Ludwig & Dr. med. Güthle
Research Overview
- Evaluation of Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide in Mild to Moderately Active Ulcerative Colitis Patients
- Comparative Efficacy of Mirikizumab Versus Azathioprine and Glucocorticoids in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: A 52-Week Randomized Trial
Data & Insights
Has run more than one trial at 6 of 38 partner sites.
Specializations
Inflammatory Bowel Disease
Leopold Ludwig’s clinical research activity is centered on ulcerative colitis, with attention to both mild-to-moderate and newly diagnosed moderate-to-severe disease. The work reflects a focus on improving disease control, symptom relief, and mucosal healing in patients managed within a gastroenterology specialty setting.
- Ulcerative colitis
- Inflammatory bowel disease
- Clinical remission
The investigator’s trial involvement is aligned with advancing therapeutic options for chronic intestinal inflammation in routine specialist care.
Symptom Control and Mucosal Healing
One area of interest is the assessment of treatments aimed at symptomatic remission, endoscopic response, and histologic improvement in active ulcerative colitis. This includes research relevant to patients whose disease remains only partially controlled and who require better long-term inflammatory suppression.
- Symptomatic remission
- Endoscopic response
- Histologic improvement
These interests place emphasis on both patient-reported benefit and objective intestinal healing.
Advanced Therapeutic Strategies
Leopold Ludwig is involved in research comparing newer targeted treatment approaches with established standard therapies in moderate-to-severe ulcerative colitis. The therapeutic landscape includes mirikizumab, azathioprine, and glucocorticoids, reflecting interest in strategies that may improve disease control in newly diagnosed patients.
- Mirikizumab
- Azathioprine
- Glucocorticoids
The focus is on treatment selection for sustained control of intestinal inflammation in a specialist gastroenterology practice.
Oral and Targeted Anti-Inflammatory Therapy
Another research interest concerns oral controlled-ileocolonic-release nicotinamide as a therapeutic option for active ulcerative colitis. This area highlights investigation of an oral anti-inflammatory approach intended to support remission and reduce ongoing inflammatory activity.
- Controlled-ileocolonic-release nicotinamide
- Oral therapy
- Anti-inflammatory treatment
The investigator’s portfolio is therefore concentrated on therapies for chronic colonic inflammation and improved disease management in ulcerative colitis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.